Sugi Predict

Sugi Predict / Compounds / SCHEMBL8044196

SCHEMBL8044196

SCHEMBL8044196

Nc1nnc(Sc2ncc([N+](=O)[O-])s2)s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 8/20 1.00
▸ MAPK9 P45984 8/20 1.00
▸ MAPK10 P53779 1/20 1.00
▸ MAPT P10636 5/20 0.56
▸ ALDH1A1 P00352 4/20 0.56
▸ HPGD P15428 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ RAB9A P51151 5/20 0.52
▸ NPC1 O15118 4/20 0.52
▸ TLR9 Q9NR96 3/20 0.52
▸ NPSR1 Q6W5P4 3/20 0.52
▸ S1PR4 O95977 2/20 0.52
▸ S1PR1 P21453 2/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ HTT P42858 2/20 0.52
▸ AGTR1 P30556 2/20 0.52
▸ HSP90AA1 P07900 1/20 0.52
▸ TDP1 Q9NUW8 2/20 0.42
▸ GAA P10253 2/20 0.41
▸ MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11430427 0.89 MAPK8 (0.79) MAPK8MAPK9MAPK10MAPTALDH1A1
SCHEMBL8048648 0.82 MAPK8 (0.69) MAPK8MAPK9MAPK10MAPTALDH1A1
SCHEMBL6746930 0.82 MAPK8 (0.69) MAPK8MAPK9MAPK10MAPTALDH1A1
SCHEMBL8051317 0.78 MAPK8 (0.64) MAPK8MAPK9MAPK10MAPTALDH1A1
SCHEMBL8046264 0.78 MAPK8 (0.64) MAPK8MAPK9MAPK10MAPTALDH1A1
SCHEMBL4786924 0.78 MAPK8 (0.64) MAPK8MAPK9MAPK10MAPTALDH1A1
SCHEMBL8037040 0.78 MAPK8 (0.67) MAPK8MAPK9MAPK10MAPTALDH1A1
SCHEMBL8046186 0.78 MAPK8 (0.67) MAPK8MAPK9MAPK10MAPTALDH1A1
SCHEMBL8033463 0.78 MAPK8 (0.64) MAPK8MAPK9MAPK10MAPTALDH1A1
SCHEMBL8052177 0.77 MAPK8 (0.62) MAPK8MAPK9MAPK10MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12469580-B2 In silico discovery of effective antimicrobials MASSACHUSETTS INSTITUTE OF TECHOLOGY (US) 2025-11-11 — — US claimed
US-20250205208-A1 USE OF SU3327 IN PREPARATION OF MEDICAMENT FOR REDUCING CYTOTOXICITY AND NEPHROTOXICITY OF POLYMYXIN XIAMEN HANLIXIN PHARMACEUTICAL CO., LTD. (CN) 2025-06-26 — — US claimed
US-20250170106-A1 USE OF SU3327 IN PREPARATION OF MEDICAMENT FOR ENHANCING EFFICACY OF POLYMYXIN AGAINST BACTERIAL INFECTION XIAMEN HANLIXIN PHARMACEUTICAL CO., LTD. (CN) 2025-05-29 — — US claimed
CN-119857105-A Antibacterial composition containing SU3327 and tannic acid, and preparation method and application thereof 中国农业大学三亚研究院 2025-04-22 — — CN claimed
CN-119818594-A Antibacterial composition and application thereof 中国农业大学 2025-04-15 — — CN claimed
CN-119817597-A Sulfur-selenium doped carbon dot and Halicin synergistic antibacterial material and preparation method thereof 安徽省儿童医院(安徽省新华医院、安徽省儿科医学研究所、复旦大学附属儿科医院安徽医院) 2025-04-15 — — CN claimed
EP-4491179-A1 USE OF SU3327 IN PREPARATION OF DRUG FOR REDUCING CYTOTOXICITY AND RENAL TOXICITY OF POLYMYXIN Xiamen Hanlixin Pharmaceutical Co., Ltd. (CN) 2025-01-15 — — EP claimed
CN-119258059-A Antibacterial composition and preparation method and application thereof 中国农业大学 2025-01-07 — — CN claimed
EP-4477219-A1 USE OF SU3327 IN PREPARING DRUG FOR ENHANCING ANTI-BACTERIAL-INFECTION EFFICACY OF POLYMYXIN Xiamen Hanlixin Pharmaceutical Co., Ltd. (CN) 2024-12-18 — — EP claimed
CN-118948843-A Use of C-JUN N-terminal kinase inhibitor SU3327 陈洪亮 2024-11-15 — — CN claimed
CN-116637109-A Use of SU3327 for restoring sensitivity to vancomycin-resistant bacteria 中国农业大学 2023-08-25 — — CN claimed
CN-116350628-A Use of SU3327 in preparation of medicament for reducing polymyxin cytotoxicity and nephrotoxicity 厦门汉力信药业有限公司 2023-06-30 — — CN claimed
CN-116236479-A Use of SU3327 in the preparation of a medicament for enhancing the efficacy of polymyxin against bacterial infection 厦门汉力信药业有限公司 2023-06-09 — — CN claimed
CN-116200330-A Method for down-regulating MAPK8 expression to induce reprogramming of cells into mammary epithelial cells 广西壮族自治区人民医院 2023-06-02 — — CN claimed
CN-113491692-B Application of C-JUN N-terminal kinase inhibitor SU3327 陈洪亮 2022-12-06 — — CN claimed
US-20220310198-A1 IN SILICO DISCOVERY OF EFFECTIVE ANTIMICROBIALS MASSACHUSETTS INSTITUTE OF TECHOLOGY (US) 2022-09-29 — — US claimed
EP-4011367-A1 COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 Dompe' Farmaceutici S.P.A. (IT) 2022-06-15 — — EP claimed
CN-112755025-A Anticancer drug, anticancer drug composition, and preparation method and application thereof 中国科学技术大学 2021-05-07 — — CN claimed
WO-2021050473-A1 IN SILICO DISCOVERY OF EFFECTIVE ANTIMICROBIALS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-03-18 — — WO claimed
US-20170191038-A1 TGFß SIGNALING INDEPENDENT NAÏVE INDUCED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USE HONG GUAN LTD (CN) 2017-07-06 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12469580-B2 In silico discovery of effective antimicrobials CGAS, CLPP, TMEM165 MAPK8 3279/4885MAPK9 2221/4885MAPK10 3398/4885
US-20220310198-A1 IN SILICO DISCOVERY OF EFFECTIVE ANTIMICROBIALS CGAS, CLPP, TMEM165 MAPK8 3279/4885MAPK9 2221/4885MAPK10 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.